Exercise may reshape your gut microbiome to support recovery
Researchers reveal how exercise-driven changes in gut microbes could influence recovery and propose a new “intestinal rehabilitation” approach…
Early B-cell therapy linked to better MS disease control
For people recently diagnosed with multiple sclerosis (MS), early treatment choices were associated with only slight differences after…
MS patients’ quality of life associated with walking performance and functional capacity
A study by the University of Eastern Finland found that quality of life in people with multiple sclerosis…
Multiple sclerosis treatment approach developed at Mainz University moves toward clinical application
A therapeutic approach pioneered in Mainz for the treatment of multiple sclerosis (MS) is taking an important step…
Brain organoid studies on the ISS move closer to new treatments
Research using human brain organoids onboard the International Space Station International Space Station (ISS) helped lead to the…
Novel salvage surgical approach for refractory multiple sclerosis-related trigeminal neuralgia
A case report in Chinese Neurosurgical Journal describes a novel salvage surgical approach for refractory multiple sclerosis-related trigeminal…
Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis
A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a…
EULAR 2026 highlights rising comorbidity risks in rheumatic disease
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases…
Ocrelizumab slows disability progression in advanced progressive multiple sclerosis
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab…
Preclinical models map genetic changes behind multiple sclerosis nerve damage
More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects…
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus…
Concerns rise over breast cancer risk and gender-based efficacy of Ocrevus
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche’s top-selling…